Natixis Advisors LLC Decreases Stock Position in Biogen Inc. $BIIB

Natixis Advisors LLC lessened its stake in Biogen Inc. (NASDAQ:BIIB) by 15.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 33,336 shares of the biotechnology company’s stock after selling 6,180 shares during the quarter. Natixis Advisors LLC’s holdings in Biogen were worth $5,867,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BIIB. Norges Bank purchased a new position in Biogen in the 4th quarter worth approximately $464,408,000. Orion Porfolio Solutions LLC boosted its holdings in Biogen by 6,828.4% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock worth $64,965,000 after acquiring an additional 509,809 shares during the period. Caisse de depot et placement du Quebec boosted its holdings in Biogen by 718.2% in the 3rd quarter. Caisse de depot et placement du Quebec now owns 569,253 shares of the biotechnology company’s stock worth $79,741,000 after acquiring an additional 499,676 shares during the period. AQR Capital Management LLC boosted its holdings in Biogen by 30.7% in the 3rd quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock worth $248,809,000 after acquiring an additional 418,776 shares during the period. Finally, Alyeska Investment Group L.P. boosted its holdings in Biogen by 66.1% in the 3rd quarter. Alyeska Investment Group L.P. now owns 845,277 shares of the biotechnology company’s stock worth $118,406,000 after acquiring an additional 336,504 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Stock Performance

Shares of BIIB opened at $192.62 on Tuesday. The business’s fifty day moving average price is $187.63 and its 200 day moving average price is $183.63. Biogen Inc. has a 12-month low of $121.05 and a 12-month high of $205.97. The stock has a market capitalization of $28.44 billion, a PE ratio of 20.67 and a beta of 0.20. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same period last year, the business posted $3.02 earnings per share. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities research analysts forecast that Biogen Inc. will post 14.18 EPS for the current year.

Analysts Set New Price Targets

BIIB has been the subject of a number of analyst reports. Citigroup upped their price target on Biogen from $190.00 to $200.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Evercore initiated coverage on Biogen in a research note on Friday, May 15th. They set an “outperform” rating for the company. Guggenheim increased their target price on Biogen from $246.00 to $260.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Argus upgraded Biogen to a “hold” rating in a research note on Thursday, April 9th. Finally, Piper Sandler reiterated an “overweight” rating and set a $225.00 target price (up from $214.00) on shares of Biogen in a research note on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Biogen has a consensus rating of “Moderate Buy” and a consensus target price of $217.26.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.